New surgery aims to stop arm swelling after melanoma treatment
NCT ID NCT06887205
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether a surgical procedure called lymphovenous bypass (LVB) can prevent lymphedema (chronic swelling) when done at the same time as lymph node removal in melanoma patients. About 20 adults with melanoma who need axillary or inguinal lymph node dissection will take part. The main goal is to check safety and see if immediate LVB reduces the risk of lymphedema compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lymphovenous bypass (LVB) procedure
- What this could lead to
- If it works, this could point toward a way to prevent lymphedema in melanoma patients who need lymph node removal.
- What could go wrong
- This is a very small pilot study with only 20 participants, so results may not apply to everyone. The procedure also carries surgical risks like any operation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants greater than or equal to 18 years of age. 2. Participants willing to participate. 3. Participants able to complete informed consent. 4. Participants with a diagnosis of Melanoma undergoing ALND or ILND. Exclusion Criteria: 1. Participant staking anticoagulants within 7 days prior to surgery. 2. Participants that are known to be pregnant at the time of surgery. 3. Participants with BMI greater than 50.0
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lymphadenectomy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can tumor DNA and immune cells reveal why some cancers resist immunotherapy?
- Can a Two-Drug immune combo shrink melanoma tumors?
- Can teaching patients about immunotherapy cut severe side effects?
- Can a triple immunotherapy attack beat advanced melanoma?
- Dye-Guided surgery may spare healthy lymph nodes in esophageal cancer